Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.69 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.69 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 11/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.62 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | HTT | P42858 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | PKM | P14618 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | CASP6 | P55212 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 10/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5323600 | 0.85 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1PDE10AMAPTALDH1A1 | |
| SCHEMBL4329054 | 0.83 | MAPT (0.69) | HSP90AA1HSP90AB1PDE10AMAPTALDH1A1 | |
| SCHEMBL2227640 | 0.82 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1PDE10AMAPTALDH1A1 | |
| SCHEMBL6634465 | 0.82 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1PDE10AMAPTALDH1A1 | |
| SCHEMBL2472343 | 0.82 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1PDE10AMAPTALDH1A1 | |
| SCHEMBL3557626 | 0.82 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1PDE10AMAPTALDH1A1 | |
| SCHEMBL5445828 | 0.81 | HSP90AA1 (0.62) | HSP90AA1HSP90AB1PDE10AMAPTALDH1A1 | |
| SCHEMBL3713823 | 0.80 | PDE10A (0.60) | HSP90AA1HSP90AB1PDE10AMAPTALDH1A1 | |
| SCHEMBL5442713 | 0.80 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1PDE10AMAPTALDH1A1 | |
| SCHEMBL29984702 | 0.80 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1PDE10AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118496154-A | Quinoline group-containing triptycene diamine monomer, polymer and preparation method | 吉林大学 | 2024-08-16 | — | — | CN | disclosed |
| CN-117865886-B | N- (quinoline-8-yl) quinoline-8-sulfonamide compound and application thereof | 中国药科大学 | 2024-05-10 | — | — | CN | disclosed |
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ZOETIS LLC | 2024-05-09 | — | — | US | disclosed |
| CN-117865886-A | N- (quinoline-8-yl) quinoline-8-sulfonamide compound and application thereof | 中国药科大学 | 2024-04-12 | — | — | CN | disclosed |
| EP-4291555-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-116806218-A | Sulfonamide and its use for the treatment of parasitic helminth infections and diseases | 新基公司 | 2023-09-26 | — | — | CN | disclosed |
| WO-2022173727-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-2970189-B1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS INC (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2970189-B1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS INC (US) | 2020-05-06 | — | — | EP | disclosed |
| CN-103492028-B | Sulfonaminoquinoline hepcidin antagonists | 维福（国际）股份公司 | 2017-02-08 | — | — | CN | disclosed |
| EP-2373650-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | Noscira, S.A. (ES) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010066832-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | NOSCIRA, S.A. (ES) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010066832-A1 | TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER | NOSCIRA, S.A. (ES) | 2010-06-17 | — | — | WO | disclosed |
| EP-2196466-A1 | Triple substituted phenanthroline derivatives for the treatment of neurodegenerative or heamatological diseases or conditions | NOSCIRA, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
| EP-2196466-A1 | Triple substituted phenanthroline derivatives for the treatment of neurodegenerative or heamatological diseases or conditions | NOSCIRA, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
| US-20010053783-A1 | Central nervous system disorders | FAIRHURST JOHN (GB) | 2001-12-20 | — | — | US | disclosed |
| EP-0854146-B1 | Substituted 4-(6-fluoro-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders | LILLY CO ELI (GB) | 2000-03-15 | — | — | EP | disclosed |
| CN-1243515-A | Substituted 4-(6-Fluoro-(1H)-indol-3-YL)-1,2,3,6-Tetra-Hydropyridine for treatment of CNS-disorders | LILLY CO ELI (GB) | 2000-02-02 | — | — | CN | disclosed |
| WO-1998031686-A1 | SUBSTITUTED 4-(6-FLUORO-(1H)-INDOL-3-YL)-1,2,3,6-TETRAHYDROPYRIDINE FOR THE TREATMENT OF CNS-DISORDERS | ELI LILLY AND COMPANY LIMITED (GB) | 1998-07-23 | — | — | WO | disclosed |
| EP-0854146-A1 | Substituted 4-(6-fluoro-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders | ELI LILLY AND COMPANY LIMITED (GB) | 1998-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ARSA, MRPS2, SULT2A1 | HSP90AA1 2179/4885HSP90AB1 2316/4885PDE10A 3320/4885 |
| US-20010053783-A1 | Central nervous system disorders | CNR1, PMP22, CNR2 | HSP90AA1 823/4885HSP90AB1 760/4885PDE10A 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.